Alternative Name(s):

UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase

Species: (Organism)

Burkholderia cenocepacia (strain ATCC BAA-245 / DSM 16553 / LMG 16656 / NCTC 13227 / J2315 / CF5610) (Burkholderia cepacia (strain J2315))

Gene Names:

lpxC

Tag info:

N-terminal 6xHis-SUMO-tagged and C-terminal Myc-tagged

Target Protein AA Sequence:

MLKQRTIKSIVKTVGIGVHSGRKIELTLRPAAPGTGIVFSRVDLPTPVDIPASAMSIGDTRLASVLQKDGVRVSTVEHLMSACAGLGIDNLYVDVTAEEIPIMDGSAATFVFLIQSAGIEEQNAPKRFIKVKKPVEIRDGDKFARLDPYFGFKLKFSIDFRHPAVDKTGQELEVDFATTSYVREIARARTFGFAHEAEMLREIGLARGGSMDNAIVLDEYRILNNDGLRYDDEFVKHKMLDAIGDLYVIGHPLLASYTAYKSGHGLNNALLRELLAHEDAYEIVTFDDPQAAPKGFAFDAQTAFA

Expression Region:

1-305aa

Subcellular Location:

Tissue Specificity:

Protein Length:

Full Length

Pathway:

Mol. Weight:

51 kDa

Purity:

Greater than 90% as determined by SDS-PAGE.

Form:

Liquid or Lyophilized powder

Buffer:

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.

Research Areas:

Others

Function:

Catalyzes the hydrolysis of UDP-3-O-myristoyl-N-acetylglucosamine to form UDP-3-O-myristoylglucosamine and acetate, the committed step in lipid A biosynthesis.

Involvement in disease:

Relevance:

Catalyzes the hydrolysis of UDP-3-O-myristoyl-N-acetylglucosamine to form UDP-3-O-myristoylglucosamine and acetate, the committed step in lipid A biosynthesis.

Reconstitution:

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Protein Families:

LpxC family

Reference:

"The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients." Holden M.T., Seth-Smith H.M., Crossman L.C., Sebaihia M., Bentley S.D., Cerdeno-Tarraga A.M., Thomson N.R., Bason N., Quail M.A., Sharp S., Cherevach I., Churcher C., Goodhead I., Hauser H., Holroyd N., Mungall K., Scott P., Walker D. Parkhill J. J. Bacteriol. 191:261-277(2009)